U.S. Peptide Therapeutics Market - Databook 2025 to 2034

The U.S. peptide therapeutics market size surpassed USD 19.86 billion in 2024 and is predicted to reach around USD 33.62 billion by 2034, registering a CAGR of 5.4% from 2025 to 2034.

Highlights of the U.S. Peptide Therapeutics Market

• By application, the metabolic disorder segment held a dominant presence in the market in 2024.
• By application, the cancer segment is expected to grow at the fastest rate in the market during the forecast period of 2025 to 2034.
• By type, the innovative segment accounted for a considerable share of the market in 2024.
• By type, the generic segment is projected to experience the highest growth rate in the market between 2025 and 2034.
• By route of administration, the parenteral segment led the market.
• By route of administration, the oral segment is set to experience the fastest rate of market growth from 2025 to 2034.
• By distribution channel, the hospital pharmacies segment registered its dominance over the market in 2024.
• By distribution channel, the online drug stores segment is anticipated to grow with the highest CAGR in the market during the studied years.
• By synthesis technology, the liquid phase peptide synthesis (LPPS) segment held a dominant presence in the market in 2024.
• By synthesis technology, the solid phase peptide synthesis (SPPS) segment is set to experience the fastest rate of market growth from 2025 to 2034.

Industry Valuation and Growth Rate Projection

The U.S. peptide therapeutics market is developing rapidly due to emerging research and techniques. Peptides, which are defined as a chain of amino acid sequences, aid in treating diseases such as cancer, diabetes, and several rare diseases. Many pharmaceutical companies have invested in peptide-based therapeutic medicine development because peptides tend to be safer for patients, and they naturally occur with characteristics that allow for preferred treatment effects in the human body.

The increasing demand for peptide therapeutics stems from patients in the U.S. wanting modern, effective, and safe therapeutic options. The U.S. government fosters this field of research and development with existing intellectual property, drug delivery systems, an expansive healthcare delivery system, and additional aspects that assist in the market opportunity for peptide therapeutics medicine in the future profits of the healthcare system.

What are the Market Trends in the U.S. Peptide Therapeutics Market?

• The market trends in the U.S. peptide therapeutics market are increasing cases of cancer and diabetes, improved technology for producing peptides, emerging routes of administration, and a focus on personalized medicine.
• More cases of cancer and diabetes: Increased occurrences of cancer and diabetes in the U.S. translate into a greater need for peptide medicines in those diseases.
• Improved technology for producing peptides: New technologies, including machinery, are enabling companies to produce peptide drugs easily and inexpensively, which companies are hoping will help them speed up the production of medicines.
• Still a focus on personalized medicine: Peptide drugs will be designed for individual patients, allowing doctors to prescribe medicines that work better for the individual patient.
• Emerging routes of administration: Medical researchers are developing means to administer peptide drugs orally as opposed to injections, which is generally more comfortable for patients.

What are the Restraints in the U.S. Peptide Therapeutics Market?

• The market restraints in the U.S. peptide therapeutics market are the high cost of producing peptides, complicated manufacturing, and peptides breaking down quickly.
• High cost of producing peptides: It is costly to produce peptide medicines, which means that more expensive prices could be passed on to the patient and lead to fewer patients receiving the medicine.
• Peptides are broken down quickly: Peptide drugs can be broken down quickly in the body, which means they may not last as long, which could mean they may need to be taken more often.
• Complicated manufacturing: The manufacture of peptide medicines is complex and requires specialized equipment, and as such, the costs of the manufacturing process can increase the time to manufacture the drug and increase the cost of the drug.

What are the Opportunities in the U.S. Peptide Therapeutics Market?

• The opportunities in the U.S. peptide therapeutics market include government support for research, combining peptides with adjunct treatment, and growing demand for limited side-effects of the medicines.
• Government support for research: The U.S. government has provided funding to scientists for the purpose of discovering new peptide medicines, which will lead to better treatment options.
• Combining peptides with adjunct treatment: The use of peptide drugs and adjunct therapies (such as immunotherapy) may enhance their efficacy for diseases such as cancer.
• Growing demand for limited side effect medicines: There is a growing demand for medicines that have fewer side effects. Because peptide drugs are known for limited side effects, this need has increased the popularity of peptide drugs.

Recent Developments in the U.S. Peptide Therapeutics Market:

• In November 2024, Aizen Therapeutics, an AI-driven biotechnology company, announced its early-stage programs powered by its novel drug discovery platform, DaX™. The development of this program is thanks to Aizen’s research team and Caltech Professor David Van Valen, MD, PhD, and represents an exceptional computational protein design model for Mirror Peptides